Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.
Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, Ogretmen B. Saddoughi SA, et al. Among authors: simon gr. Clin Cancer Res. 2011 Sep 15;17(18):6097-105. doi: 10.1158/1078-0432.CCR-11-0930. Epub 2011 Jul 26. Clin Cancer Res. 2011. PMID: 21791630 Free PMC article. Clinical Trial.
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI. Homsi J, et al. Among authors: simon gr. Clin Cancer Res. 2007 Oct 1;13(19):5855-61. doi: 10.1158/1078-0432.CCR-06-2821. Clin Cancer Res. 2007. PMID: 17908979 Clinical Trial.
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Chiappori AA, et al. Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508. Clin Cancer Res. 2008. PMID: 18316570 Clinical Trial.
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.
Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. Hong DS, et al. Clin Cancer Res. 2011 Oct 15;17(20):6582-91. doi: 10.1158/1078-0432.CCR-11-0430. Epub 2011 Aug 10. Clin Cancer Res. 2011. PMID: 21831956 Free PMC article. Clinical Trial.
125 results